Chandrashekar Kiran, Lopez-Ruiz Arnaldo, Juncos Ramiro, Nath Karl, Stec David E, Vera Trinity, Liu Ruisheng, Juncos Luis A
Division of Nephrology, Department of Medicine, University of Mississippi Medical Center, Jackson, MS 39216, USA.
Int J Hypertens. 2012;2012:392890. doi: 10.1155/2012/392890. Epub 2012 Mar 11.
Angiotensin II (AngII) causes hypertension (HTN) and promotes renal injury while simultaneously inducing reno-protective enzymes like heme oxygenase-1 (HO-1). We examined the modulatory role of HO on sub-pressor angiotensin II (SP-AngII) induced renal inflammation and injury. We first tested whether the SP-AngII-induced renal dysfunction, inflammation and injury are exacerbated by either preventing (chronic HO-1 inhibition) or reversing (late HO-1 inhibition) SP-AngII-induced HO (using tin protoporphyrin; SnPP). We next examined whether additional chronic or late induction of SP-AngII-induced HO (using cobalt protoporphyrin; CoPP), prevents or ameliorates renal damage. We found that neither chronic nor late SnPP altered blood pressure. Chronic SnPP worsened SP-AngII-induced renal dysfunction, inflammation, injury and fibrosis, whereas late SnPP worsened renal dysfunction but not inflammation. Chronic CoPP prevented HTN, renal dysfunction, inflammation and fibrosis, but surprisingly, not the NGAL levels (renal injury marker). Late CoPP did not significantly alter SP-AngII-induced HTN, renal inflammation or injury, but improved renal function. Thus, we conclude (a) endogenous HO may be an essential determining factor in SP-AngII induced renal inflammation, injury and fibrosis, (b) part of HO's renoprotection may be independent of blood pressure changes; and (c) further induction of HO-1 protects against renal injury, suggesting a possible therapeutic target.
血管紧张素II(AngII)可导致高血压(HTN)并促进肾损伤,同时诱导血红素加氧酶-1(HO-1)等肾保护酶。我们研究了HO对亚升压剂量血管紧张素II(SP-AngII)诱导的肾炎症和损伤的调节作用。我们首先测试了通过预防(慢性HO-1抑制)或逆转(晚期HO-1抑制)SP-AngII诱导的HO(使用锡原卟啉;SnPP),SP-AngII诱导的肾功能障碍、炎症和损伤是否会加剧。接下来,我们研究了额外慢性或晚期诱导SP-AngII诱导的HO(使用钴原卟啉;CoPP)是否能预防或改善肾损伤。我们发现,慢性或晚期SnPP均未改变血压。慢性SnPP使SP-AngII诱导的肾功能障碍、炎症、损伤和纤维化恶化,而晚期SnPP使肾功能障碍恶化,但未使炎症恶化。慢性CoPP可预防高血压、肾功能障碍、炎症和纤维化,但令人惊讶的是,对中性粒细胞明胶酶相关脂质运载蛋白水平(肾损伤标志物)无效。晚期CoPP未显著改变SP-AngII诱导的高血压、肾炎症或损伤,但改善了肾功能。因此,我们得出结论:(a)内源性HO可能是SP-AngII诱导的肾炎症、损伤和纤维化的关键决定因素;(b)HO的部分肾保护作用可能独立于血压变化;(c)进一步诱导HO-1可预防肾损伤,提示其可能为治疗靶点。